Locus Coeruleus Ablation Exacerbates Cognitive Deficits, Neuropathology, and Lethality in P301S Tau Transgenic Mice

• Authors: Termpanit Chalermpalanupap, Emory University; Jason P Schroeder, Emory University; Jacki M. Rorabaugh, Emory University; L. Cameron Liles, Emory University; James J Lah, Emory University; Allan I Levey, Emory University; David Weinshenker, Emory University
• Journal Title: Journal of Neuroscience
• Volume: Volume 38, Number 1
• Publisher: Society for Neuroscience | 2018-01-03, Pages 74-92
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.1523/JNEUROSCI.1483-17.2017
• Subjects: Biology, Genetics; Health Sciences, Medicine and Surgery
• Keywords: Science & Technology; Life Sciences & Biomedicine; Neurosciences; Neurosciences & Neurology; DSP-4; hippocampus; locus coeruleus; neuroinflammation; norepinephrine; tau; DOPAMINE-BETA-HYDROXYLASE; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; SPATIAL NAVIGATION; SENILE-DEMENTIA; MOUSE MODEL; CERULEUS DEGENERATION; CIRCADIAN-RHYTHMS; APP/PS1 MICE; PATHOLOGY

Abstract

The brainstem locus coeruleus (LC) supplies norepinephrine to the forebrain and degenerates in Alzheimer’s disease (AD). Loss of LC neurons is correlated with increased severity of other AD hallmarks, including -amyloid (A) plaques, tau neurofibrillary tangles, and cognitive deficits, suggesting that it contributes to the disease progression. Lesions of the LC in amyloid-based transgenic mouse models of AD exacerbate A pathology, neuroinflammation, and cognitive deficits, but it is unknown how the loss of LC neurons affects tau-mediated pathology or behavioral abnormalities. Here we investigate the impact of LC degeneration in a mouse model of tauopathy by lesioning the LC of male and female P301S tau transgenic mice with the neurotoxin N-(2-chloroethyl)-N-ethyl-bromobenzylamine (DSP-4) starting at 2 months of age. By 6 months, deficits in hippocampal-dependent spatial (Morris water maze) and associative (contextual fear conditioning) memory were observed in lesioned P301S mice while performance remained intact in all other genotype and treatment groups, indicating that tau and LC degeneration act synergistically to impair cognition. By 10 months, the hippocampal neuroinflammation and neurodegeneration typically observed in unlesioned P301S mice were exacerbated by DSP-4, and mortality was also accelerated. These DSP-4-induced changes were accompanied by only a mild aggravation of tau pathology, suggesting that increased tau burden cannot fully account for the effects of LC degeneration. Combined, these experiments demonstrate that loss of LC noradrenergic neurons exacerbates multiple phenotypes caused by pathogenic tau, and provides complementary data to highlight the dual role LC degeneration has on both tau and A pathologies in AD.